AUSTIN, Texas—Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NASDAQ:NTRA), recently sold shares of the company's common stock, according to a filing with the Securities and Exchange Commission. The transactions, which took place on October 21 and 22, involved the sale of 550 shares, amounting to a total value of $66,241.
The shares were sold at prices ranging from $120.07 to $120.7591 per share. Following these transactions, Moshkevich holds 111,891 shares of Natera. The sales were conducted to satisfy tax obligations related to the vesting of restricted stock units, as noted in the filing.
In other recent news, Natera Inc . has secured a permanent injunction against NeoGenomics (NASDAQ:NEO)' RaDaR assay, following a preliminary injunction in December 2023. The decision by the District Court for the Middle District of North Carolina is part of Natera's broader efforts to protect its intellectual property rights within the genetic testing market.
In financial highlights, Natera reported a 12% sequential revenue increase and a 58% year-over-year surge. The company is projecting a 40% revenue growth compared to 2023. Analyst firms Piper Sandler, TD Cowen, and Canaccord Genuity have maintained positive stances on Natera, reiterating their price targets and Buy ratings.
These developments come as Natera's Signatera test is poised to impact oncological discussions by providing insights on overall survival and disease-free survival. The company's Renasight test also received an endorsement from the National Kidney Foundation for chronic kidney disease testing. These are among the recent developments that underscore Natera's commitment to growth and innovation in the personalized genetic testing and diagnostics space.
InvestingPro Insights
While Solomon Moshkevich's recent stock sale may raise eyebrows, it's essential to view this transaction in the broader context of Natera's financial performance and market position. According to InvestingPro data, Natera's market capitalization stands at an impressive $14.72 billion, reflecting strong investor confidence in the company's future prospects.
Natera has demonstrated remarkable revenue growth, with a 46.13% increase over the last twelve months as of Q2 2024, reaching $1.36 billion. This growth trajectory is further emphasized by the company's quarterly revenue growth of 58.13% in Q2 2024, indicating accelerating momentum in its business operations.
InvestingPro Tips highlight that Natera has achieved a high return over the last year, with a staggering 190.88% price total return. This exceptional performance aligns with the company's strong revenue growth and suggests that investors have been rewarding Natera's business expansion.
However, it's worth noting that Natera is not yet profitable, with a negative operating income of $313.73 million over the last twelve months. This is reflected in the company's price-to-earnings ratio of -50.23, indicating that investors are betting on future profitability rather than current earnings.
For investors seeking a more comprehensive analysis, InvestingPro offers additional insights with 11 more tips available for Natera. These tips could provide valuable context for understanding the company's financial health and growth prospects beyond the recent insider transaction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.